Search Results

Structural Analysis of DFG-in and DFG-out Dual Src-Abl Inhibitors Sharing a Common Vinyl Purine Template

Authors: Zhou, Tianjun; Commodore, Lois; Huang, Wei-Sheng; Wang, Yihan; Sawyer, Tomi K.; Shakespeare, William C.; Clackson, Tim; Zhu, Xiaotian; Dalgarno, David C.

Source: Chemical Biology & Drug Design, Volume 75, Number 1, January 2010 , pp. 18-28(11)

Publisher: Blackwell Publishing

Nilotinib: Bronchitis and gastritis: case report

Source: Reactions, Volume 1, Number 1279, 2009-11-21 , pp. 26-26(1)

Publisher: Adis International

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties

Authors: Hegedűs, C; Özvegy-Laczka, C; Apáti, Á; Magócsi, M; Német, K; Őrfi, L; Kéri, G; Katona, M; Takáts, Z; Váradi, A; Szakács, G; Sarkadi, B

Source: British Journal of Pharmacology, Volume 158, Number 4, October 2009 , pp. 1153-1164(12)

Publisher: Blackwell Publishing

Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells

Authors: Krauth, M.-T.; Mirkina, I.; Herrmann, H.; Baumgartner, C.; Kneidinger, M.; Valent, P.

Source: Clinical & Experimental Allergy, Volume 39, Number 11, November 2009 , pp. 1711-1720(10)

Publisher: Blackwell Publishing

in vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs)

Authors: Marfe, Gabriella; Stefano, Carla D.

Source: Recent Patents on Anti-Cancer Drug Discovery, Volume 5, Number 1, January 2010 , pp. 58-68(11)

Publisher: Bentham Science Publishers

Imatinib/nilotinib: Skin eruption with imatinib, followed by bone marrow aplasia with nilotinib (first report), in an elderly patient: case report

Source: Reactions, Volume 1, Number 1267, 2009-08-29 , pp. 21-21(1)

Publisher: Adis International

Nilotinib: Hyperbilirubinaemia: case report

Source: Reactions, Volume 1, Number 1263, 2009-08-01 , pp. 24-24(1)

Publisher: Adis International

Nilotinib-induced bone marrow aplasia

Authors: Song, Moo-Kon; Choi, Young-Jin; Seol, Young-Mi; Shin, Ho-Jin; Chung, Joo-Seop; Cho, Goon-Jae; Lee, Eun-Yup

Source: European Journal of Haematology, Volume 83, Number 2, August 2009 , pp. 161-162(2)

Publisher: Blackwell Publishing

Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro

Authors: Kircher, Brigitte; Schumacher, Petra; Petzer, Andreas; Hoflehner, Elisabeth; Haun, Margot; Wolf, Anna Maria; Nachbaur, David; Gastl, Günther

Source: European Journal of Haematology, Volume 83, Number 1, July 2009 , pp. 48-56(9)

Publisher: Blackwell Publishing

A Bayesian Case Study in Oncology Phase I Combination Dose-Finding Using Logistic Regression with Covariates

Authors: Bailey, Stuart; Neuenschwander, Beat; Laird, Glen; Branson, Michael

Source: Journal of Biopharmaceutical Statistics, Volume 19, Number 3, May 2009 , pp. 469-484(16)

Publisher: Taylor and Francis Ltd

Nilotinib Therapy in Chronic Myelogenous Leukemia: The Strength of High Selectivity on BCR/ABL

Authors: Breccia, Massimo; Alimena, Giuliana

Source: Current Drug Targets, Volume 10, Number 6, June 2009 , pp. 530-536(7)

Publisher: Bentham Science Publishers

Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia

Authors: Gruber, Franz; Mustjoki, Satu; Porkka, Kimmo

Source: British Journal of Haematology, Volume 145, Number 5, June 2009 , pp. 581-597(17)

Publisher: Blackwell Publishing

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation

Authors: Ocheni, Sunday; Iwanski, Gabriela; Schafhausen, Philippe; Zander, Axel Rolf; Ayuk, Francis; Klyuchnikov, Evgeny; Zabelina, Tatjana; Fiedler, Walter; Schnittger, Susanne; Hochhaus, Andreas; Brummendorf, Tim; Kroger, Nicolaus; Bacher, Ulrike

Source: Leukemia and Lymphoma, Volume 50, Number 4, April 2009 , pp. 551-558(8)

Publisher: Informa Healthcare

Nilotinib inhibits the Src-family kinase LCK and T-cell function in vitro

Source: Journal of Cellular and Molecular Medicine, Volume 13, Number 3, March 2009 , pp. 599-601(3)

Publisher: Blackwell Publishing

New approved dasatinib regimen available for clinical use

Author: Snyder, David S

Source: Expert Review of Anticancer Therapy, Volume 9, Number 3, March 2009 , pp. 285-292(8)

Publisher: Expert Reviews

Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem

Authors: Breccia, Massimo; Alimena, Giuliana

Source: Cardiovascular & Haematological Disorders - Drug Targets(Formerly Current D, Volume 9, Number 1, March 2009 , pp. 21-28(8)

Publisher: Bentham Science Publishers

Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy

Authors: Pytel, Dariusz; Sliwinski, Tomasz; Poplawski, Tomasz; Ferriola, Deborah; Majsterek, Ireneusz

Source: Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry, Volume 9, Number 1, January 2009 , pp. 66-76(11)

Publisher: Bentham Science Publishers

BCR/ABL, DNA damage and DNA repair: Implications for new treatment concepts

Author: Skorski, Tomasz

Source: Leukemia and Lymphoma, Volume 49, Number 4, March 2008 , pp. 610-614(5)

Publisher: Informa Healthcare

Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

Authors: Hantschel, Oliver; Rix, Uwe; Superti-Furga, Giulio

Source: Leukemia and Lymphoma, Volume 49, Number 4, March 2008 , pp. 615-619(5)

Publisher: Informa Healthcare

Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia

Authors: Clark, Richard; Davies, Andrea; Pirmohamed, Munir; Giannoudis, Athina

Source: Leukemia and Lymphoma, Volume 49, Number 4, March 2008 , pp. 639-642(4)

Publisher: Informa Healthcare